iltamiocel (AMDC-GIR)

About Cook MyoSite

Cook MyoSite is a private, clinical-stage biotech leveraging over 20 years of expertise in muscle cell technology to develop regenerative therapies. Its core asset is iltamiocel, an autologous muscle-derived cell therapy with FDA RMAT designation, currently in Phase III trials for stress urinary incontinence and fecal incontinence, and Phase II/III for oropharyngeal dysphagia. The company also generates early revenue through a Laboratory Research Services division, offering characterized primary cells and custom services to the research community under an ISO9001-certified quality system.

Therapeutic Areas